Sexualsteroide und ihre onkogene Potenz

Bradlow HL, Sepkovic W (2004) Steroids as procarcinogenic agents. Ann NY Acad Sci 1028:216–232

Chen WY, Manson JAE, Hankinson SE et al (2006) Unopposed estrogen therapy and the risk of invasive breast cancer. Arch Intern Med 166:1027–1032

Chlebowski RT, Kuller LH, Prentice RL et al (2009) Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 360:573–587

Chlebowski RT, Schwartz AG, Wakelee H et al (2009) Oestrogen plus progestin and lung cancer in postmenopausal women (Women’s Health Initiative trial): a post-hoc analysis of a randomized controlled trial. Lancet 374:1243–1251

Come SE, Buzdar AU, Ingle JN et al (2005) Proceedings of the Fourth International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res 11 (Suppl):861s–864s

Dietel M, Lewis MA, Shapiro S (2005) Hormone replacement therapy: pathological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review. Hum Reprod 20:2052–2060

Doherty JA, Weiss NS, Freeman RJ et al (2005) Genetic factors in catechol estrogen metabolism in relation to the risk of endometrial cancer. Cancer Epidemiol Biomarkers Prev 14:357–366

Dunn BK, Wickerham DL, Ford LG (2005) Prevention of hormone-related cancers: breast cancer. J Clin Oncol 23:357–367

Eliassen AH, Missmer SA, Tworoger SS et al (2006) Endogenous steroid hormone concentrations and risk of breast cancer among premenopausal women. J Natl Cancer Inst 98:1406–1415

Ellis MJ, Gao F, Dehdashti F et al (2009) Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer. A phase 2 randomized study. JAMA 302:774–780

Emons G, Fleckenstein G, Hinney B et al (2000) Hormonal interactions in endometrial cancer. Endocr Relat Cancer 7:227–242

Emons G, Huschmand-Nia A, Krauss T, Hinney B (2004) Hormonal replacement therapy and endometrial cancer. Onkologie 27:207–210

Fisher B, Costantino JP, Wickerham DL et al (2005) Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97:1652–1662

Gorski J, Kennedy RD, Hosey AM, Harkin DP (2009) The complex relationship between BRCA1 and ERα in hereditary breast cancer. Clin Cancer Res 15:1514–1518

Grady D, Gebretsiak T, Kerlikowske K et al (1995) Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304–313

Ho S-M (2003) Estrogen, progesterone and epithelial ovarian cancer. Reprod Biol Endocrinol 1:73–81

Jordan VC (2009) A century of deciphering the control mechanisms of sex steroid action in breast and prostate cancer: the origins of targeted therapy and chemoprevention. Cancer Res 69:1243–1254

Katalinic A, Lemmer A, Zawinell A et al (2009) Trends in hormone therapy and breast cancer incidence – results from the German Network of Cancer Registries. Pathobiology 76:90–97

Kreienberg R, Kopp I, Albert U et al (2008) Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Deutsche Krebsgesellschaft e.V. (DKG) und Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG). W. Zuckschwerdt GmbH

Lindgren PR, Cajander S, Bäckström T et al (2004) Estrogen and progesterone receptors in ovarian epithelial tumors. Mol Cell Endocrinol 221:97–104

Micheli A, Meneghini E, Secreto G et al (2007) Plasma testosterone and prognosis of postmenopausal breast cancer patients. J Clin Oncol 25:2685–2690

Missmer SA, Eliassen AH, Barbieri L, Hankinson SE (2004) Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J Natl Cancer Inst 96:1856–1865

Morch LS, Lokkegaard E, Andreasen AH et al (2009) Hormone therapy and ovarian cancer. JAMA 302:298–305

Ravdin PM, Cronin KA, Howlader N et al (2007) The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356:1670–1674

Rebbeck TR, Troxel AB, Shatalova EG et al (2007) Lack of effect modification between estrogen metabolism genotypes and combined hormone replacement therapy in postmenopausal breast cancer risk. Cancer Epidemiol Biomarkers Prev 16:1318–1320

Rogan EG, Badawi AF, Devanesan PP et al (2003) Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 24:697–702

Santen R, Cavalieri E, Rogan E et al (2009) Estrogen mediation of breast tumor formation involves estrogen receptor-dependent, as well as independent genotoxic effects. Ann N Y Acad Sci 1155:132–140

Tamimi RM, Hankinson SE, Chen WY et al (2006) Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. Arch Intern Med 166:1483–1489

Visvanathan K, Chlebowski RT, Hurley P et al (2009) American Society of Clinical Oncology Clinical Practice Guideline Update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol 19:3235–3258

Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354:270–282

Yue W, Santen RJ, Wang JP et al (2003) Genotoxic metabolites of estradiol in breast: potential mechanism of estradiol induced carcinogenesis. J Steroid Biochem Mol Biol 86:477–486

Yue W, Wang JP, Li Y et al (2005) Tamoxifen versus aromatase inhibitors for breast cancer prevention. Clin Cancer Res 11 (Suppl):925s–930s